|
Targeted Candidalysin Binders for Fungal Infection Control
Application
A theranostic scaffold-derived protein that neutralizes candidalysin toxin.
Key Benefits
Different mechanism of action compared to current antifungal drugs, reducing the risk of resistance.
Derived from human protein for lower immune response and produced cost-effectively in simple bacterial media.
Small size improves tissue penetration...
Published: 2/23/2026
Contributor(s): Sohail Khoshnevis, Eric J. Sundberg, Maros Huliciak
|
|
Methioninase Inducing Virus for Anti-Cancer Therapy
Application
A set of viral constructs that induce regulatable expression of methionine degrading enzyme for treatment of brain tumors.
Key Benefits
Built-in Tet-responsive element ensures precise regulation, preventing unwanted enzyme activity.
IL-2 signal directs the enzyme for secretion, optimizing its therapeutic impact.
Specific delivery...
Published: 1/20/2026
Contributor(s): Timothy R. Gershon, Leon McSwain, Andrey Tikunov
|
|
Precision Protein Repair Platform for Missense Mutations
Application
This technology enables targeted chemical correction of missense mutations in proteins using a modular heterotrifunctional molecule platform.
Key Benefits
Restores protein function by chemically mimicking healthy amino acid side chains.
Modular toolkit allows rapid customization for diverse protein targets.
Validated across multiple...
Published: 11/12/2025
Contributor(s): Monika Raj
|
|
Gene Editing for Head and Neck Cancer Treatment
Application
Method for delivering gene-editing therapeutic in head and neck cancers.
Key Benefits
CRISPR/CAS9-based gene editing mechanism targeting novel disease-modifying gene.
Liquid nanoparticle encapsulation permitting in vivo delivery.
Market Summary
Head and neck cancers (HNC) are the 7th most common global cancer, accounting for 3%...
Published: 11/7/2025
Contributor(s): Yong Teng, Yamin Li
|
|
Anticancer Agent with N-Glycan Specificity
Application
An engineered protein for targeting disease-associated N-glycans.
Key Benefits
High affinity, pH insensitive, no cofactors required.
Applications in anticancer and antiviral therapeutics and research.
Can aid in manufacturing monoclonal antibodies with desired N-glycosylation properties.
Market Summary
Glycosylation involves post-translation...
Published: 1/20/2026
Contributor(s): Eric J. Sundberg, Diego Sastre, Maros Huliciak
|
|
Treatment for Dengue Virus (DENV) Infection
Application
Antiviral therapeutic for multiple Dengue virus serotypes.
Key Benefits
Targets conserved regions of DENV genomes, enabling efficacy across serotypes.
Mitigates lethal infections with a single lipid nanoparticle (LNP) based dose in mice.
Minimal off-target effects.
Market Summary
Despite 390+ million annual DENV infections, there...
Published: 2/23/2026
Contributor(s): Philip Santangelo, Daryll Vanover, Chiara Zurla, Lorena Carvalho de Souza Chaves
|
|
Combinatorial Therapy for Preserving Muscle Mass During Weight Loss
Application
A combinatorial therapy to preserve muscle mass during semaglutide weight loss treatment.
Key Benefits
Preserves lean mass during semaglutide treatment in preclinical mouse models.
Increases overall fat loss without affecting food/water intake during semaglutide treatment in preclinical mouse models.
Market Summary
The prevalence...
Published: 2/23/2026
Contributor(s): Todd Golde, Yong Ran, Eric Krause, Annette De Kloet, Karen Scott
|
|
MKK3/MYC Protein-Protein Interaction Inhibitor Overcomes Resistant Non-Small Cell Lung Cancer
Application
A therapeutic use for SGI-1027 in the treatment of Osimertinib-resistant non-small cell lung cancer (NSCLC).
Key Benefits
The MKK3/MYC protein-protein interaction inhibitor SGI-1027 effectively decreases MYC levels in Osimertinib-resistant NSCLC cell lines.
The combination of SGI-1027 with Osimertinib offers synergistic benefits over...
Published: 12/5/2025
Contributor(s): Andrey Ivanov, Haian Fu, Shi-Yong Sun, Zhen Chen
|
